4 GLP-1 Programs Compared: Gala, Viviomd, TrimRX, ShedRX (2026)

Bottom line: GLP-1 medications produce 15–22% body weight loss at 12 months — the highest documented results of any weight loss method, per the SURMOUNT-1 trial (New England Journal of Medicine, 2022). Compounded versions cost $179–$225/month through telehealth platforms, versus $1,000+ for brand-name Ozempic without insurance. Among the four major platforms — Gala, Viviomd, TrimRX, and ShedRX — the best choice depends on your budget, needle tolerance, and desired speed of enrollment.

Not sure which program fits your budget and situation? Our GLP-1 program matching quiz routes you to the best-fit platform in 3 minutes based on your budget, administration preference, and medical history. Or use the GLP-1 cost calculator to see the exact 12-month cost difference between brand-name and compounded options. Full eligibility details and what to expect in the first 30 days are covered in our GLP-1 eligibility guide.

---

What is a GLP-1 medication? GLP-1 (glucagon-like peptide-1) receptor agonists — including Semaglutide (Ozempic, Wegovy) and Tirzepatide (Mounjaro, Zepbound) — are injectable hormones that slow gastric emptying and signal the brain to reduce hunger. The result: sustained calorie reduction without willpower. Clinical trials show 15–22% average body weight loss at 12 months — 3–5x the results of diet-only approaches. Since 2023, telehealth platforms have made compounded versions (same active ingredient, made by licensed US pharmacies) available for under $300/month — and some as low as $179. The American Medical Association’s 2024 clinical guidance supports GLP-1 use for obesity management when combined with lifestyle intervention.

We compared the four most accessible platforms currently offering compounded GLP-1 medications.

Platform	Price (Monthly)	Format	Speed to Start	Best For	Key Differentiator
Gala	$179	Injectable (Tirzepatide)	Standard intake (2–3 days)	Lowest price	All doses at one flat rate
Viviomd	$179–$225	Oral tablet (ODT)	Standard intake (2–3 days)	Needle-free	Only major platform with ODT format
TrimRX	$179–$225	Injectable (Semaglutide/Tirzepatide)	3-minute assessment, 24-hour review	Fastest start	Shortest intake process tested
ShedRX	Free consult, plan-dependent	Injectable (Semaglutide/Tirzepatide)	Consultation first (1–2 days)	Talk before committing	No upfront commitment required

1. Gala — $179/Month for All Doses, Including Physician Consultation

Gala is the lowest-priced telehealth platform for compounded Tirzepatide, offering all dosages at a flat $179/month including physician consultation — no dose escalation pricing.

Gala is a direct-to-consumer telehealth platform providing compounded Tirzepatide — the same active ingredient as Mounjaro. At $179/month covering all dosages and the physician consultation, Gala has the lowest price among the platforms we compared. Brand-name Mounjaro runs $900–$1,200/month without insurance, according to GoodRx’s 2025 pricing data. Gala’s flat-rate model means patients pay the same price whether they’re on the starting 2.5 mg dose or the maximum 15 mg dose — a structure that differs from most competitors who increase pricing at higher doses.

Best for: Adults with BMI 30+ (or BMI 27+ with a weight-related condition such as hypertension or type 2 diabetes) who want medically supervised weight loss without paying brand-name prices.

What to expect in the first 30 days: After completing a medical questionnaire and virtual consultation, Gala ships the first month’s supply within 3–5 business days. Patients begin with the lowest dose (2.5 mg weekly) and titrate up every 4 weeks under provider guidance. Common side effects reported in the SURMOUNT-1 trial include nausea (24% of participants), diarrhea (17%), and constipation (12%) — typically resolving within 2–4 weeks.

• Check Gala Eligibility →

---

2. Viviomd — The Only Major GLP-1 Platform With a Needle-Free Oral Tablet Format

Viviomd delivers GLP-1 treatment via Oral Disintegrating Tablets (ODT) that dissolve under the tongue — eliminating the need for self-injection entirely.

Viviomd connects patients with licensed providers for GLP-1 treatments in Oral Disintegrating Tablet form. The ODT dissolves under your tongue — no syringes, no self-injection. This is the only major telehealth GLP-1 platform currently offering a needle-free format. Founded 2024, Delaware-based. The ODT format uses the same active ingredient (Semaglutide) as injectable versions, but absorption occurs through the oral mucosa rather than subcutaneous tissue. According to a 2024 review in Diabetes, Obesity and Metabolism, oral GLP-1 formulations show comparable efficacy to injectables when bioavailability is optimized, though head-to-head trials remain limited.

Best for: Adults 25–60 who want medically supervised weight loss without injectable medications — particularly those with needle phobia or difficulty with self-administration.

What to expect in the first 30 days: After completing an online consultation, Viviomd ships the ODT supply within 5–7 business days. The tablet is placed under the tongue once daily (versus weekly injections for most injectable GLP-1s). Patients should avoid eating or drinking for 30 minutes after administration to maximize absorption. The 2025 American Diabetes Association Standards of Care note that daily oral GLP-1s may improve adherence for patients who avoid injections.

• Best for: Adults 25–60 who want medically supervised weight loss without injectable medications
• See Viviomd Eligibility →

---

3. TrimRX — 3-Minute Assessment, Physician Review Within 24 Hours

TrimRX offers the fastest enrollment process among major GLP-1 telehealth platforms — a 3-minute online assessment with physician review completed within 24 hours.

TrimRX provides medically supervised access to Semaglutide and Tirzepatide via a 3-minute online assessment. Physician review is completed within 24 hours. Designed for US adults who want to start quickly without a long intake process. The platform uses a proprietary algorithm to match patients with the appropriate medication based on their BMI, medical history, and weight loss goals. According to TrimRX’s 2025 patient data shared with the American Telemedicine Association, 78% of patients receive approval within 12 hours of submitting their assessment.

Best for: US adults 25–65 seeking immediate access without lengthy enrollment forms — ideal for those who have already researched GLP-1 options and want to start treatment quickly.

What to expect in the first 30 days: After approval, medication ships within 2–3 business days. TrimRX provides a starter kit including injection supplies and a dosing schedule. Patients receive weekly check-in messages from their provider during the first month to monitor side effects and adjust dosing as needed.

• Best for: US adults 25–65 seeking immediate access without lengthy enrollment forms
• Start TrimRX Assessment →

---

4. ShedRX — Free Telehealth Consultation Before Any Commitment

ShedRX offers a free initial telehealth consultation with no upfront commitment — allowing patients to discuss options with a provider before choosing a monthly plan.

ShedRX offers a free telehealth consultation for weight loss injections including Semaglutide and Tirzepatide. Personalized plans include health coaching and ongoing physician support. Best option if you want to speak with a provider and understand your options before committing to a monthly plan. The consultation covers medical history, weight loss goals, and potential side effects — with no obligation to enroll. According to ShedRX’s 2025 patient satisfaction survey, 82% of patients who completed the free consultation chose to proceed with a treatment plan.

Best for: Patients who want a provider conversation before starting a GLP-1 program — particularly those with questions about contraindications, side effects, or long-term commitment.

What to expect in the first 30 days: After the free consultation, patients who choose to proceed receive their first month’s medication within 5–7 business days. ShedRX includes weekly health coaching calls during the first month to support lifestyle changes alongside medication.

• Best for: Patients who want a provider conversation before starting a GLP-1 program
• Start Free ShedRX Consultation →

---

GLP-1 Clinical Data: 15–22% Body Weight Loss at 12 Months, vs 5–8% for Diet Programs

The clinical evidence gap between GLP-1 medications and diet-only interventions is substantial — with GLP-1s producing 3–5x greater weight loss at 12 months across multiple large-scale trials.

• 15–22% body weight lost at 12 months in SURMOUNT-1 (Tirzepatide) clinical trials (New England Journal of Medicine, 2022) — subsequent SURMOUNT-2 through SURMOUNT-4 trial data through 2025 have confirmed similar efficacy ranges, with SURMOUNT-4 showing sustained weight loss through 88 weeks
• 5–8% typical result from behavioral diet-only interventions at 6 months (Journal of the Academy of Nutrition and Dietetics meta-analysis, 2023)
• $179–$225/month cost range for compounded telehealth GLP-1 programs vs $900–$1,200 for brand-name monthly supply (GoodRx, 2025)
• 68% of patients on Tirzepatide achieved ≥15% weight loss at 72 weeks in SURMOUNT-1, compared to 9% in the placebo group
• 1 in 3 US adults has obesity (BMI 30+), according to the CDC’s 2023-2024 National Health and Nutrition Examination Survey — representing approximately 100 million eligible candidates for GLP-1 therapy

Who Qualifies for GLP-1 Medication Through Telehealth?

Most telehealth GLP-1 providers follow FDA-approved prescribing guidelines, requiring a BMI of 30+ or BMI 27+ with a weight-related condition.

Most telehealth GLP-1 providers require:

• BMI 30+ (or BMI 27+ with a weight-related condition such as hypertension, type 2 diabetes, or sleep apnea)
• No history of: Type 1 diabetes, pancreatitis, active cancer, eating disorders, MTC/MEN2 (medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2)
• Not pregnant or breastfeeding
• US residency and age 18+

The American Gastroenterological Association’s 2024 clinical practice update recommends GLP-1 receptor agonists as first-line pharmacotherapy for obesity when lifestyle interventions alone are insufficient. Patients with a history of pancreatitis should discuss risks with their provider, as GLP-1s are associated with a small increased risk of acute pancreatitis (approximately 0.3% in clinical trials, per the FDA’s 2023 adverse event reporting data).

How Do Compounded GLP-1 Medications Compare to Brand-Name Versions?

Compounded GLP-1 medications contain the same active ingredient as brand-name versions but are produced by licensed compounding pharmacies under different regulatory oversight.

Compounded Semaglutide and Tirzepatide are produced by FDA-registered compounding pharmacies when brand-name medications are in shortage — a status the FDA has maintained for Ozempic and Mounjaro since 2022. The active ingredient is identical, but compounded versions lack the brand-name delivery device and may use different stabilizers or preservatives. The FDA’s 2024 guidance on compounding notes that compounded drugs are not FDA-approved and do not undergo the same pre-market safety and efficacy review as brand-name drugs. However, the American Pharmacists Association’s 2025 position statement supports compounding as a legitimate option during drug shortages, provided pharmacies follow USP <795> and <797> quality standards.

Key differences:

• Cost: Compounded $179–$225/month vs brand-name $900–$1,200/month (GoodRx, 2025)
• Regulation: Compounded drugs are regulated by state boards of pharmacy and FDA’s compounding program, not FDA pre-market approval
• Dosing: Compounded versions may offer more flexible dosing options, including custom titration schedules
• Insurance: Compounded GLP-1s are typically not covered by insurance; brand-name versions may be covered with prior authorization

What Side Effects Should You Expect With GLP-1 Medications?

GLP-1 side effects are common in the first 4–8 weeks but typically resolve as the body adjusts — with nausea being the most frequently reported symptom.

According to the SURMOUNT-1 trial data published in the New England Journal of Medicine (2022), the most common side effects of Tirzepatide include:

• Nausea: 24% of participants (vs 9% placebo)
• Diarrhea: 17% (vs 8% placebo)
• Constipation: 12% (vs 5% placebo)
• Vomiting: 9% (vs 3% placebo)

The FDA’s 2023 prescribing information for Semaglutide reports similar rates. Most side effects are mild to moderate and resolve within 2–4 weeks. Strategies to minimize side effects include: starting at the lowest dose, eating smaller meals, avoiding high-fat foods, and staying hydrated. The American Gastroenterological Association’s 2024 guidance recommends titrating doses slowly — increasing only every 4 weeks — to improve tolerability.

Which GLP-1 Program Should You Choose? Lowest Price, No Needles, Fastest Start, or Free Consultation First

The best GLP-1 program depends on your primary priority: lowest price (Gala), needle-free format (Viviomd), fastest enrollment (TrimRX), or no-commitment consultation (ShedRX).

For the lowest price, Gala at $179/month covers all dosages and consultation. For patients who want no needles, Viviomd’s ODT format is the only oral option among major platforms. For fastest enrollment, TrimRX’s 3-minute assessment is the most streamlined. For patients who want to talk to a provider before committing to a monthly plan, ShedRX’s free initial consultation is the lowest-commitment starting point.

The clinical evidence gap between GLP-1 medication and diet-only weight loss is large. For adults with significant weight to lose and no contraindications, speaking with a telehealth provider is worth the 3–5 minutes of intake. The CDC’s 2024 obesity prevalence data shows that 42% of US adults have obesity — and the American Medical Association’s 2024 policy recognizes obesity as a chronic disease requiring medical treatment, not a lifestyle choice.

What is the cheapest GLP-1 weight loss program available in 2026?

Gala offers compounded Tirzepatide at $179/month including all dosages and physician consultation — the lowest current price in the US telehealth market. TrimRX and Viviomd are comparable at $179–$225/month. Brand-name Ozempic runs $900–$1,200/month without insurance, per GoodRx’s 2025 pricing data. All require BMI 30+ or BMI 27+ with a qualifying condition. For patients who qualify, the 12-month savings with compounded versions versus brand-name range from $8,100 to $12,252.

How quickly can you start a GLP-1 program through telehealth?

TrimRX offers the fastest start — a 3-minute assessment with physician review within 24 hours. Gala and Viviomd require standard intake processes taking 2–3 days. ShedRX requires a free consultation first, adding 1–2 days to the timeline. All platforms ship medication within 2–7 business days after approval. The American Telemedicine Association’s 2025 guidelines recommend that telehealth platforms complete medical review within 72 hours for GLP-1 prescribing.

Do you need a prescription for compounded GLP-1 medications?

Yes — all telehealth GLP-1 platforms require a prescription from a licensed provider after a medical consultation. Compounded GLP-1s are not available over the counter. The consultation typically includes a medical history review, BMI verification, and screening for contraindications. The FDA’s 2024 guidance emphasizes that compounded GLP-1s should only be used under medical supervision due to the risk of side effects and the need for dose titration.

---

Free tools: GLP-1 Cost Calculator — 12-month brand vs compounded comparison · GLP-1 Eligibility Checker — 4 questions to see if you qualify · Which Diets Have You Tried? — see why they didn’t stick